EVMN

Latest SEC Filings & News for EVMN

1 most recent filing and news item mentioning EVMN. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/EVMN/news?limit=20"

Pull EVMN filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
OtherJun 29, 2026Positive

Evommune pivots EVO756 away from CSU after Phase 2b trial failure

Evommune disclosed that its Phase 2b trial of EVO756 failed to meet the primary endpoint for chronic spontaneous urticaria. The company will discontinue development in this indication but will use its cash runway to advance the candidate in atopic dermatitis and migraine.

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.